Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer

Detalles Bibliográficos
Autores principales: Kurozumi, Sasagu, Katayama, Ayaka, Shirabe, Ken, Horiguchi, Jun, Rakha, Emad A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2021
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555688/
https://www.ncbi.nlm.nih.gov/pubmed/34733421
http://dx.doi.org/10.18632/oncotarget.28007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555688/
https://www.ncbi.nlm.nih.gov/pubmed/34733421
http://dx.doi.org/10.18632/oncotarget.28007

Ejemplares similares